Aptima® Mycoplasma Genitalium Assay

Mycoplasma genitalium (M. gen) is an emerging health concern.

Testing for M. gen is recommended for all patients with recurrent urethritis, cervicitis and PID.1 Both women and men with M. gen infections are often asymptomatic and when left untreated, this infection can result in serious health consequences.

  • Frequently asymptomatic.
  • Detected in 10%-30% of women with clinical cervicitis.
  • Identified in up to 22% of pelvic inflammatory disease (PID) cases.
  • Untreated PID can lead to adverse pregnancy outcomes.
  • More likely to exhibit symptoms of M. gen infection.
  • Responsible for 40% of persistent or recurrent urethritis in men.

Proper treatment depends on proper diagnosis.

Often misdiagnosed, M. gen presents similar symptoms with other urogenital tract bacterial infections, such as Trichomoniasis, Chlamydia or Gonorrhea.However, treatment for these infections is organism-specific. Accurate diagnosis is critical to ensuring infections are treated successfully.

NAAT is the CDC recommended method for detection of M. gen.

When identifying M. gen, the test you choose matters. Infections carry very low bacterial loads, and each organism contains 1000s of rRNA copies versus only one copy of DNA. RNA-based NAAT is far more sensitive than DNA-based tests.

DNA-based tests can miss 40% of infections compared to rRNA-based tests.

The rRNA-based Aptima Mycoplasma genitalium assay provides up to 100% sensitivity.

Streamline testing for sexual and vaginal health.

Test for M. gen with the Aptima Multitest swab. The Aptima portfolio powers efficient, streamlined testing with assay and collection consolidation on scalable automation.


Alternative Specimen Collection Also Available


Female urine (first catch)
Male urine (first catch)


Unisex Swab

Endocervical swabs
Male urethral swabs